Success Metrics

Clinical Success Rate
94.1%

Based on 32 completed trials

Completion Rate
94%(32/34)
Active Trials
6(11%)
Results Posted
47%(15 trials)
Terminated
2(4%)

Phase Distribution

Ph phase_4
3
6%
Ph phase_3
14
26%
Ph not_applicable
7
13%
Ph phase_2
23
43%
Ph phase_1
4
8%

Phase Distribution

4

Early Stage

23

Mid Stage

17

Late Stage

Phase Distribution51 total trials
Phase 1Safety & dosage
4(7.8%)
Phase 2Efficacy & side effects
23(45.1%)
Phase 3Large-scale testing
14(27.5%)
Phase 4Post-market surveillance
3(5.9%)
N/ANon-phased studies
7(13.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.4%

32 of 35 finished

Non-Completion Rate

8.6%

3 ended early

Currently Active

6

trials recruiting

Total Trials

53

all time

Status Distribution
Active(12)
Completed(32)
Terminated(3)
Other(6)

Detailed Status

Completed32
Not yet recruiting6
unknown5
Recruiting3
Active, not recruiting3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
53
Active
6
Success Rate
94.1%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (7.8%)
Phase 223 (45.1%)
Phase 314 (27.5%)
Phase 43 (5.9%)
N/A7 (13.7%)

Trials by Status

withdrawn12%
completed3260%
not_yet_recruiting611%
suspended12%
unknown59%
recruiting36%
terminated24%
active_not_recruiting36%

Recent Activity

Clinical Trials (53)

Showing 20 of 53 trialsScroll for more
NCT06253715Phase 3

Shortened Regimen for Drug-susceptible TB in Children

Recruiting
NCT06192160Phase 2

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
NCT04311502Phase 2

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Terminated
NCT07656012Phase 2

Re-evaluating the Duration in Children of TB Treatment

Not Yet Recruiting
NCT07595042Phase 2

A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)

Not Yet Recruiting
NCT04930744Phase 2

Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)

Completed
NCT05556746Phase 2

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Active Not Recruiting
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT05807399Phase 2

PanACEA - STEP2C -01

Recruiting
NCT02563327Phase 3

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Completed
NCT05766267Phase 2

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active Not Recruiting
NCT06917495Phase 2

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Not Yet Recruiting
NCT06081361Phase 3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort

Active Not Recruiting
NCT02754765Phase 3

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Completed
NCT04179500Phase 2

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

Completed
NCT02619994Phase 2

Treatment Shortening of MDR-TB Using Existing and New Drugs

Completed
NCT04717908Not Applicable

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

Completed
NCT03338621Phase 2

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Completed
NCT05047055

Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients

Unknown
NCT04694586Phase 2

Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide

Suspended

Drug Details

Intervention Type
DRUG
Total Trials
53